HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Zentalis Pharma (NASDAQ:ZNTL) but lowers the price target from $40 to $20.

June 18, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Zentalis Pharma but lowers the price target from $40 to $20.
The Buy rating suggests confidence in the company's long-term prospects, but the significant reduction in the price target indicates concerns about short-term performance or valuation, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100